CCDM Regulatory Requirements 5 — Questions and Answers
Question 1: What is the primary regulatory basis for requiring a Statistical Analysis Plan (SAP) to be finalized before database lock in a clinical trial?
- To prevent post-hoc analysis decisions that could introduce bias into the trial results (Correct answer)
- To satisfy the IRB requirement for statistical oversight of the study
- To meet the FDA requirement for SAP submission with the IND application
- To document that the biostatistician has GCP training certification
Correct answer: To prevent post-hoc analysis decisions that could introduce bias into the trial results
Pre-specifying analyses in a finalized SAP before unblinding prevents data-driven changes to analysis methods that could bias results and undermine regulatory submission integrity.
Question 2: Which FDA regulation defines the requirements for investigator recordkeeping and record retention at clinical trial sites?
- 21 CFR 312.62 (Correct answer)
- 21 CFR Part 11
- 21 CFR 312.32
- 21 CFR Part 50
Correct answer: 21 CFR 312.62
21 CFR 312.62 specifies that investigators must maintain adequate records of drug disposition and case histories and retain them for at least 2 years after the marketing application approval.
Question 3: Under CDISC standards adopted by the FDA for electronic submissions, which standard governs the format of clinical trial data tabulations?
- SDTM (Study Data Tabulation Model) (Correct answer)
- CDASH (Clinical Data Acquisition Standards Harmonization)
- ADaM (Analysis Data Model)
- ODM (Operational Data Model)
Correct answer: SDTM (Study Data Tabulation Model)
SDTM defines a standard structure for organizing and formatting clinical trial data tabulations submitted to the FDA as part of regulatory submissions.
Question 4: When a clinical trial site loses its essential documents due to a natural disaster, what is the investigator's regulatory obligation?
- Notify the sponsor and IRB immediately and take steps to reconstruct or replace lost records to the extent possible (Correct answer)
- Immediately withdraw all subjects from the study and terminate the trial at that site
- File a formal complaint with the FDA within 24 hours of discovering the loss
- Notify only the sponsor and await further instructions before taking any action
Correct answer: Notify the sponsor and IRB immediately and take steps to reconstruct or replace lost records to the extent possible
Investigators must promptly notify sponsors and IRBs of lost essential documents and make reasonable efforts to reconstruct lost records, as regulators may still require them during inspections.
Question 5: According to the FDA's guidance on computerized systems in clinical investigations, what is required when making corrections to electronic clinical data?
- The original entry must be preserved, the correction made with date, time, and identity of the person making the change, and a reason provided (Correct answer)
- The incorrect entry must be permanently deleted and replaced with the correct value
- A paper form documenting the correction must be submitted to the FDA within 30 days
- The system administrator must approve all data corrections before they are saved
Correct answer: The original entry must be preserved, the correction made with date, time, and identity of the person making the change, and a reason provided
FDA guidance requires that audit trails preserve original data, and corrections must include the who, when, and why of each change without obscuring the original entry.
Question 6: What is the regulatory significance of 'blinding' or 'masking' in randomized controlled trials from a data management perspective?
- It prevents knowledge of treatment assignment from influencing data collection, entry, or analysis, reducing bias (Correct answer)
- It encrypts the clinical database to protect participant confidentiality under HIPAA
- It restricts data access to only the principal investigator and sponsor
- It hides adverse event data from IRB review until the trial is complete
Correct answer: It prevents knowledge of treatment assignment from influencing data collection, entry, or analysis, reducing bias
Maintaining treatment blinding during data collection and management prevents conscious or unconscious bias in how data is recorded, queried, or interpreted before unblinding.
Question 7: Which regulatory requirement mandates that all clinical trial participants must be registered in a public database before enrollment begins for trials of FDA-regulated products?
- Section 801 of the FDA Amendments Act (FDAAA 801), implemented through ClinicalTrials.gov (Correct answer)
- ICH E6 R2 requirement for subject identification in the trial master file
- 21 CFR Part 50 requirement for informed consent documentation
- The HIPAA Privacy Rule authorization for research use of health data
Correct answer: Section 801 of the FDA Amendments Act (FDAAA 801), implemented through ClinicalTrials.gov
FDAAA 801 requires registration of applicable clinical trials of FDA-regulated products on ClinicalTrials.gov before enrollment begins, with results reporting requirements after completion.
CCDM Regulatory Requirements 5
What is the primary regulatory basis for requiring a Statistical Analysis Plan (SAP) to be finalized before database lock in a clinical trial?